You are viewing the site in preview mode
Skip to main content
|
Variable
|
Total N = 119
|
Alive N = 96
|
Dead N = 23
|
p
|
|---|
|
Age at CMR (years)
|
50.5 (±10.2)
|
49.8 (±9.7)
|
53.7 (±11.5)
|
0.05*
|
|
Male (%)
|
83 (69.7)
|
71 (74.0)
|
12 (52.2)
|
0.04*
|
|
BSA (m2)
|
1.84 (±0.3)
|
1.86 (±0.3)
|
1.77 (±0.2)
|
0.12
|
|
BMI (kg/m2)
|
25.0 (±4.7)
|
24.9 (±0.7)
|
25.4 (±4.5)
|
0.12
|
|
Systolic BP (mmHg)
|
138 (±23)
|
137 (±23)
|
141 (±24.2)
|
0.38
|
|
Diastolic BP (mmHg)
|
82 (±12.7)
|
82 (±13)
|
81 (±13)
|
0.77
|
|
RRT time to CMR (years)
|
2.2 (0.6, 5.2)
|
1.7 (0.7, 3.9)
|
2.5 (0.6, 5.8)
|
0.57
|
|
RRT
| | | | |
|
HD
|
100 (84.0)
|
84 (87.5)
|
16 (69.5)
|
0.91
|
|
PD
|
19 (16.0)
|
11 (11.4)
|
8 (34.7)
|
|
Diabetes mellitus
|
73 (61.3)
|
61 (63.5)
|
12 (52.2)
|
0.32
|
|
Ischemic heart disease
|
17 (14.3)
|
13 (13.5)
|
4 (17.4)
|
0.64
|
|
Heart failure
|
6 (5.0)
|
5 (5.2)
|
1 (4.3)
|
0.86
|
|
Cerebrovascular disease
|
12 (10.1)
|
6 (6.3)
|
6 (26.1)
|
0.005*
|
|
Peripheral vascular disease
|
7 (5.9)
|
4 (4.2)
|
3 (13.0)
|
0.10
|
|
Dyslipidemia
|
34 (28.6)
|
26 (27.1)
|
8 (34.8)
|
0.46
|
|
Smoking
| | | | |
|
Never
|
52 (43.7)
|
44 (45.8)
|
8 (34.8)
|
0.14
|
|
Current/Ex smoker
|
67 (56.3)
|
52 (54.2)
|
15 (65.2)
|
|
Epo receptor agonist
|
92 (77.3)
|
74 (77.9)
|
18 (78.3)
|
0.97
|
|
β adrenoceptor blocker
|
40 (33.6)
|
35 (37.6)
|
5 (21.7)
|
0.15
|
|
Aspirin
|
32 (26.9)
|
26 (28.0)
|
6 (26.1)
|
0.86
|
|
Warfarin
|
5 (4.2)
|
2 (2.2)
|
3 (13.0)
|
0.08
|
|
ACEI/ARB pre-transplant
|
25 (21.0)
|
22 (23.4)
|
3 (13.0)
|
0.28
|
|
Diuretic
|
30 (25.2)
|
24 (25.8)
|
6 (26.1)
|
0.98
|
|
Calcium channel blocker
|
29 (24.4)
|
23 (24.7)
|
6 (26.1)
|
0.89
|
|
α adrenoceptor blocker
|
10 (8.4)
|
9 (9.7)
|
1 (4.3)
|
0.42
|
|
Statin
|
34 (28.6)
|
26 (28.0)
|
8 (34.8)
|
0.52
|
|
Hemoglobin (g/l)
|
117 (±17)
|
117 (±1.7)
|
117 (±1.8)
|
0.97
|
|
CRP
|
6.0 (4.0, 41.2)
|
6.0 (4.0, 12.0)
|
19 (4.0, 49.5)
|
0.19
|
|
Corrected calcium (mmol/l)
|
2.42 (±0.4)
|
2.41 (±0.4)
|
2.42 (±0.5)
|
0.97
|
|
Phosphate (mmol/l)
|
1.67 (±0.4)
|
1.71 (±0.4)
|
1.52 (±0.5)
|
0.30
|
|
Albumin (g/l)
|
41.5 (±4.3)
|
42.5 (±3.7)
|
37.5 (±4.7)
|
0.008*
|
|
Ejection fraction (%)
|
66.3 (±10.2)
|
66.3 (±9.5)
|
66.4 (±12.3)
|
0.99
|
|
LVSD on MRI (EF < 55%)
|
16 (13.4)
|
11 (11.5)
|
5 (21.7)
|
0.19
|
|
Myocardial mass/BSA (g/m2)
|
96.4 (±31.7)
|
95.2 (±31.7)
|
101.6 (±32.4)
|
0.38
|
|
LVH
|
78 (65.5)
|
58 (60.4)
|
20 (87.0)
|
0.16
|
|
ESV/BSA (ml/m2)
|
25.1 (±14.8)
|
72.4 (±25.7)
|
73.5 (±25.2)
|
0.85
|
|
EDV/BSA (ml/m2)
|
72.7 (±25.5)
|
24.9 (±13.8)
|
25.9 (±18.9)
|
0.77
|
|
LV dilation
|
14 (13.4)
|
11 (11.5)
|
3 (13.0)
|
0.83
|
|
LA volume/BSA (ml/m2)
|
32.1 (±7.7)
|
31.0 (±6.7)
|
36.4 (±9.1)
|
0.01*
|
- Data are numbers with percentage in parentheses, mean ± standard deviation or median (interquartile range). Tests of significance are t-test (parametric), Mann-Whitney (non-parametric) and Chi-square. Abbreviations: CMR cardiovascular MRI, RRT renal replacement therapy, HD hemodialysis, PD peritoneal dialysis, Epo erythropoietin stimulating agent, ACEI/ARB angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker, BSA body surface area, BMI body mass index. *p < 0.05.
